Efficacy and safety of haloperidol versus atypical antipsychotic medications in the treatment of delirium

BMC Psychiatry

Table 2 Group comparisons of serial changes in DRS-K and K-MMSE scores

Efficacy measures		Haloperidol	Risperidone	Olanzapine	Quetiapine	Total	Sig.
DRS-K
Severity score	Baseline	17.4 ± 6.7	18.9 ± 5.2	17.5 ± 5.7	17.5 ± 6.4	17.8 ± 6.0	0.779^†
	Day 2	11.5 ± 7.1	13.3 ± 5.8	10.5 ± 6.6	12.2 ± 5.4	11.93 ± 6.2
	Day 4	8.5 ± 4.6	9.8 ± 6.7	8.8 ± 6.0	7.6 ± 3.7	8.80 ± 5.4
	Day 6	7.7 ± 5.4	8.3 ± 7.1	8.1 ± 5.5	6.5 ± 4.0	7.75 ± 5.5
Cognitive subscale score	Baseline	7.8 ± 3.8	8.7 ± 3.4	7.7 ± 3.6	8.1 ± 3.2	8.14 ± 3.5	0.718^†
	Day 2	5.7 ± 3.9	6.5 ± 3.4	5.0 ± 3.0	5.6 ± 2.6	5.76 ± 3.3
	Day 4	4.3 ± 2.4	4.8 ± 3.6	4.2 ± 3.2	4.0 ± 2.5	4.43 ± 3.0
	Day 6	4.0 ± 2.9	4.1 ± 4.0	4.2 ± 2.7	3.2 ± 2.5	3.94 ± 3.1
non-cognitive subscale score	Baseline	9.5 ± 3.5	10.1 ± 3.0	9.7 ± 3.3	9.4 ± 4.2	9.73 ± 3.4	0.918^†
	Day 2	5.7 ± 3.5	6.5 ± 2.9	5.5 ± 3.8	6.6 ± 3.7	6.11 ± 3.4
	Day 4	4.1 ± 2.6	4.9 ± 3.8	4.6 ± 3.5	3.6 ± 2.2	4.41 ± 3.1
	Day 6	3.7 ± 2.8	4.2 ± 3.6	3.9 ± 3.5	3.3 ± 2.0	3.81 ± 3.0
K-MMSE score
	Baseline	13.7 ± 6.5	15.0 ± 5.8	16.2 ± 5.4	15.7 ± 6.3	15.1 ± 6.0	0.630^†
	Day 2	19.0 ± 6.7	18.3 ± 5.7	21.0 ± 6.2	20.2 ± 4.9	19.5 ± 5.9
	Day 4	21.3 ± 4.7	21.5 ± 5.3	21.8 ± 5.8	21.9 ± 3.7	21.6 ± 4.9
	Day 6	22.4 ± 4.4	22.4 ± 5.0	23.1 ± 5.3	23.4 ± 3.7	22.8 ± 4.6

Data were presented as mean ± SD.
†: p-values analyzed among groups by linear mixed model statistics.
Each day-by-group interaction was not significant in all efficacy measures.
(all p-values analyzed by linear mixed model statistics >0.05).
In all medication groups, the mean score of DRS-K severity, cognitive and non-cognitive subscale tended to decrease significantly over study period.
(all p-values analyzed by linear mixed model statistics < 0.0001).
In all medication groups, the mean score of K-MMSE tended to increase significantly over the study period. (all p-values analyzed by linear mixed model statistics < 0.0001).

ISSN: 1471-244X